HRP20220664T1 - 1h-indazol-3-karboksamid spojevi kao inhibitori glikogen sintaza kinaze 3 beta - Google Patents
1h-indazol-3-karboksamid spojevi kao inhibitori glikogen sintaza kinaze 3 beta Download PDFInfo
- Publication number
- HRP20220664T1 HRP20220664T1 HRP20220664TT HRP20220664T HRP20220664T1 HR P20220664 T1 HRP20220664 T1 HR P20220664T1 HR P20220664T T HRP20220664T T HR P20220664TT HR P20220664 T HRP20220664 T HR P20220664T HR P20220664 T1 HRP20220664 T1 HR P20220664T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- indazole
- alkyl
- alkoxy
- heterocyclic ring
- Prior art date
Links
- 150000008581 1H-indazole-3-carboxamides Chemical class 0.000 title claims 7
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 title claims 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 title claims 2
- 239000003112 inhibitor Substances 0.000 title 1
- -1 1H-indazole-3-carboxamide compound Chemical class 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000001931 aliphatic group Chemical group 0.000 claims 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 150000007522 mineralic acids Chemical class 0.000 claims 3
- 150000007524 organic acids Chemical class 0.000 claims 3
- 125000005475 oxolanyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 201000009916 Postpartum depression Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 208000025748 atypical depressive disease Diseases 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 208000012672 seasonal affective disease Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000009810 Catatonic Schizophrenia Diseases 0.000 claims 1
- 208000001495 Disorganized Schizophrenia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000036755 Schizophrenia simple Diseases 0.000 claims 1
- 208000036754 Schizophrenia, catatonic type Diseases 0.000 claims 1
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 claims 1
- 208000036750 Schizophrenia, residual type Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010007776 catatonia Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000026725 cyclothymic disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000005458 thianyl group Chemical group 0.000 claims 1
- 125000001166 thiolanyl group Chemical group 0.000 claims 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18171084 | 2018-05-07 | ||
| PCT/EP2019/061532 WO2019215075A1 (en) | 2018-05-07 | 2019-05-06 | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| EP19721295.4A EP3790873B1 (en) | 2018-05-07 | 2019-05-06 | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220664T1 true HRP20220664T1 (hr) | 2022-06-24 |
Family
ID=62134122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220664TT HRP20220664T1 (hr) | 2018-05-07 | 2019-05-06 | 1h-indazol-3-karboksamid spojevi kao inhibitori glikogen sintaza kinaze 3 beta |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11472795B2 (enExample) |
| EP (1) | EP3790873B1 (enExample) |
| JP (1) | JP7411574B2 (enExample) |
| KR (1) | KR102778690B1 (enExample) |
| CN (1) | CN112135821B (enExample) |
| AU (1) | AU2019265606B2 (enExample) |
| BR (1) | BR112020021922A2 (enExample) |
| CA (1) | CA3094896A1 (enExample) |
| CY (1) | CY1125293T1 (enExample) |
| DK (1) | DK3790873T3 (enExample) |
| EA (1) | EA202092422A1 (enExample) |
| ES (1) | ES2913975T3 (enExample) |
| GE (2) | GEP20227437B (enExample) |
| HR (1) | HRP20220664T1 (enExample) |
| HU (1) | HUE058894T2 (enExample) |
| IL (1) | IL278330B2 (enExample) |
| LT (1) | LT3790873T (enExample) |
| MA (1) | MA52557A (enExample) |
| MD (1) | MD3790873T2 (enExample) |
| MX (1) | MX2020011882A (enExample) |
| PL (1) | PL3790873T3 (enExample) |
| PT (1) | PT3790873T (enExample) |
| RS (1) | RS63255B1 (enExample) |
| SG (1) | SG11202009230WA (enExample) |
| SI (1) | SI3790873T1 (enExample) |
| SM (1) | SMT202200227T1 (enExample) |
| UA (1) | UA128089C2 (enExample) |
| WO (1) | WO2019215075A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4079732A4 (en) * | 2019-12-16 | 2023-10-18 | Korea Research Institute of Chemical Technology | NEW INDAZOLE DERIVATIVE AND ITS USE |
| CN114230565B (zh) * | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| JP7746384B2 (ja) * | 2020-12-08 | 2025-09-30 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１のベンゾピラゾール阻害剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0667867A1 (en) | 1992-11-05 | 1995-08-23 | Smithkline Beecham Plc | Piperidine derivatives as 5-ht4 receptor antagonists |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| ITMI20030287A1 (it) | 2003-02-18 | 2004-08-19 | Acraf | Indazolammidi dotate di attivita' analgesica metodo, per |
| ITMI20030972A1 (it) | 2003-05-15 | 2004-11-16 | Acraf | Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende. |
| KR101061599B1 (ko) * | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| IN2014CN02646A (enExample) * | 2011-09-14 | 2015-08-07 | Samumed Llc | |
| BR112014018657B1 (pt) | 2012-02-21 | 2022-08-02 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A | Compostos de 1h-indazol-3-carboxamida |
| AU2013224302B2 (en) | 2012-02-21 | 2017-03-30 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| CN106535890A (zh) | 2014-03-20 | 2017-03-22 | 萨穆梅德有限公司 | 5‑取代的吲唑‑3‑羧酰胺及其制备和应用 |
| EP3755696B1 (en) * | 2018-02-23 | 2023-04-05 | BioSplice Therapeutics, Inc. | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
-
2019
- 2019-05-06 ES ES19721295T patent/ES2913975T3/es active Active
- 2019-05-06 CA CA3094896A patent/CA3094896A1/en active Pending
- 2019-05-06 RS RS20220482A patent/RS63255B1/sr unknown
- 2019-05-06 HR HRP20220664TT patent/HRP20220664T1/hr unknown
- 2019-05-06 MA MA052557A patent/MA52557A/fr unknown
- 2019-05-06 SI SI201930227T patent/SI3790873T1/sl unknown
- 2019-05-06 GE GEAP201915506A patent/GEP20227437B/en unknown
- 2019-05-06 DK DK19721295.4T patent/DK3790873T3/da active
- 2019-05-06 EP EP19721295.4A patent/EP3790873B1/en active Active
- 2019-05-06 PL PL19721295T patent/PL3790873T3/pl unknown
- 2019-05-06 KR KR1020207030163A patent/KR102778690B1/ko active Active
- 2019-05-06 SM SM20220227T patent/SMT202200227T1/it unknown
- 2019-05-06 LT LTEPPCT/EP2019/061532T patent/LT3790873T/lt unknown
- 2019-05-06 MX MX2020011882A patent/MX2020011882A/es unknown
- 2019-05-06 US US17/051,352 patent/US11472795B2/en active Active
- 2019-05-06 SG SG11202009230WA patent/SG11202009230WA/en unknown
- 2019-05-06 PT PT197212954T patent/PT3790873T/pt unknown
- 2019-05-06 MD MDE20210228T patent/MD3790873T2/ro unknown
- 2019-05-06 HU HUE19721295A patent/HUE058894T2/hu unknown
- 2019-05-06 EA EA202092422A patent/EA202092422A1/ru unknown
- 2019-05-06 GE GEAP202215506A patent/GEAP202215506A/en unknown
- 2019-05-06 CN CN201980029405.9A patent/CN112135821B/zh active Active
- 2019-05-06 UA UAA202006085A patent/UA128089C2/uk unknown
- 2019-05-06 BR BR112020021922-3A patent/BR112020021922A2/pt unknown
- 2019-05-06 AU AU2019265606A patent/AU2019265606B2/en active Active
- 2019-05-06 WO PCT/EP2019/061532 patent/WO2019215075A1/en not_active Ceased
- 2019-05-06 JP JP2020562568A patent/JP7411574B2/ja active Active
- 2019-05-06 IL IL278330A patent/IL278330B2/en unknown
-
2022
- 2022-05-26 CY CY20221100366T patent/CY1125293T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220664T1 (hr) | 1h-indazol-3-karboksamid spojevi kao inhibitori glikogen sintaza kinaze 3 beta | |
| JOP20220247A1 (ar) | مثبطات كرومينون تفارغية لفوسفوينوسيتيد 3 كيناز (pi3k) لعلاج أمراض مرتبطة بتعديل p13k | |
| AR116978A1 (es) | Fungicidas de tolilo sustituido | |
| PE20252677A1 (es) | Amidas de azolipiridina piridazinona como inhibidores de sos1 | |
| PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
| BRPI0809770B8 (pt) | Composto e composição para controlar uma praga de invertebrados | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PH12014502866A1 (en) | Fungicidal heterocyclic carboxamides | |
| PE20160126A1 (es) | Derivados del bipirazol como inhibidores jak | |
| HRP20160125T1 (hr) | Spojevi 1h-indazol-3-karboksamida kao inhibitori glikogen sinteze kinaze-3 beta | |
| AR086121A1 (es) | Derivados de oxazina y una composicion farmaceutica para inhibir bace1 que los contienen | |
| NZ626068A (en) | Multicyclic compounds and methods of use thereof | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| HRP20160124T1 (hr) | Uporaba spojeva 1h-indazol-3-karboksamida kao inhibitora glikogen sinteze kinaze-3 beta | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| JP2015506993A5 (enExample) | ||
| ES2653419T3 (es) | Pirazolopirimidinilamino-indazoles sustituidos | |
| NZ601967A (en) | Pde10 inhibitors and related compositions and methods | |
| HRP20140687T1 (hr) | Derivati benzofurana | |
| ECSP11011384A (es) | Sales de adición de trometamina con derivados de ácido azabifenilaminobenzoico como inhibidores de dhodh. | |
| KR102803762B1 (ko) | Pi3-키나제 및 오토파지 경로의 조절인자로서의 트리-치환된 아릴 및 헤테로아릴 유도체 | |
| PE20210175A1 (es) | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| PE20090880A1 (es) | Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa | |
| CO6241119A2 (es) | Compuestos de pirido 2,3-d pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer | |
| MY162998A (en) | Ethynyl derivatives |